Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flavopiridol in Advanced Renal Cell Cancer
NCT00016939Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2001
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alvocidib in renal cell carcinoma (RCC), sponsored by SWOG Cancer Research Network. Primary endpoint: Objective Response Rate up to 3 years. Started May 2001; status: completed.
02
Drugs
alvocidib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00016939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016939.